Journal
FUTURE MEDICINAL CHEMISTRY
Volume 4, Issue 17, Pages 2153-2161Publisher
FUTURE SCI LTD
DOI: 10.4155/FMC.12.169
Keywords
-
Categories
Funding
- Academy of Finland
- EVO [5503726]
- Finnish Cultural Foundation
- Finnish Eye Foundation
- Finnish Funding Agency for Technology and Innovation
- Paivikki and Sakari Sohlberg Foundation
Ask authors/readers for more resources
Age-related macular degeneration (AMD) is the leading cause of central vision loss in the elderly in the developed countries. The number of AMD patients will double during the next decades due to increasing number of aged people. Chronic oxidative stress, inflammation and accumulation of protein-rich deposits both in the retinal pigment epithelium lysosomes and under the retinal pigment epithelium herald the onset of AMD. The disease can be divided into dry and wet AMD forms. The dry form of the disease is more prevalent accounting for up to 90% of all cases. Continued intraocular injections are the current treatment strategy to prevent progression of wet AMD. It is a major challenge to develop new drugs that could prevent or at least ease the symptoms of the increasing population of AMD patients. Since AMD pathology is clearly associated with accumulated protein deposits, the autophagy clearance system might represent a potential future therapeutic target for AMD as is thoroughly discussed here.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available